Value-based drug pricing offers an important way to bring down the high cost of drugs in the United States.
In this approach, a drug’s price is tied to demonstrated effectiveness and benefit on patient outcomes. Results-based pricing is built into contracts between pharmaceutical manufacturers, health care payers, and health care providers. The more effective a drug, the higher the target price payers submit, with discounts and rebates given for drugs that are less effective than expected.
Traditional, fee-for-service contracts are still dominant in drug pricing today, but the transition to value-based care is accelerating in the health care industry, especially in Europe, according to a McKinsey study. And while the U.S. lags behind in adopting value-based agreements, many policymakers are realizing that value-based pricing can be an important, viable solution to the high and rising expenditures that payers lay out for prescription drugs.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect